Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy

DISEASE CHARACTERISTICS: * Cytomegalovirus (CMV) seropositive * Patient has had CMV antigenemia for ≥ 2 weeks OR CMV DNA levels ≥ 600 copies/μg of DNA despite antiviral therapy targeting CMV (ganciclovir or foscarnet) * No prior allogeneic stem cell transplantation before the most recent transplantation * CMV seropositive donor negative for HIV-1, HIV-2, HTLV-1/2 available PATIENT CHARACTERISTICS: * ECOG performance status 0-2 (for patients ≤ 16 years of age) OR Lansky performance status 70-100% * Bilirubin \< 2.0 mg/dL * AST and ALT \< 2.5 times upper limit of normal * Creatinine clearance \> 50 mL/min * Pulse oximetry \> 95% without supplemental oxygen * No history of graft-vs-host disease (GVHD) ≥ grade 2 * Not moribund * No patients not expected to survive 1 month after T cell infusion due to cardiac, pulmonary, renal, hepatic, or neurologic dysfunction PRIOR CONCURRENT THERAPY: * No concurrent systemic immunosuppressive agents for the treatment of GVHD